

# PECEIVED FOR 2 3 2002 FOR CENTER 1600/290

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Evan C. Unger, et al.

Serial No.: 09/699,679

Group Art Unit: 1617

Filed: October 30, 2000

Examiner: Michael A. Willis

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND

THERAPEUTIC USE

I, S. Maurice Valla, Registration No. 43,966 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On August 14, 2002

S. Maurice/Valla, Reg. No. 43,966

# **BOX SEQUENCE**

Assistant Commissioner for Patents Washington, D.C. 20231

# STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

$\boxtimes$	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
•	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
×	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the





# **DOCKET NO.: UNGR-1598**

**PATENT** 

	application, as filed. does (do) not include	•	at the substitute sl	heet(s) of the Se	equence Listing
	I hereby state that the accordance with 37 C		-	·	
	I hereby state that the accordance with 37 C		-		
August	14, 2002		S. Maurice Valla Registration No.		<u> </u>

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

**©** 1997 WWKMN



PATEND BOX SEA

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE'

In l	Re	Ap	plica	tion	of:
------	----	----	-------	------	-----

Evan C. Unger, et al.

Confirmation No.: 8248

Serial No.: 09/699,679

Group Art Unit: 1617

Filing Date: October 30, 2000

Examiner: Michael A. Willis

For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND

THERAPEUTIC USE

DATE OF DEPOSIT: August 14, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER

TYPED NAME: S. Maurice Valla REGISTRATION NO.: 43,966

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, Virginia 22202

Sir:

#### REPLY TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

	A Preliminary Amendment.
$\boxtimes$	An Amendment Responsive to the Office Action Dated <u>April 23, 2002</u> .
	An Amendment Supplemental to the Paper filed
	Other:

DISK TO STIC

$\boxtimes$	Applicant(s) has previously claimed small entity status under 37 CFR §1.27.					
	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:					
	□ an Independent Inventor □ a Small Business Concern					
	a Nonprofit Organization					
	This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.					
	Loss of Entitlement Enclosed					
	Substitute Pages of the Specification are enclosed.					
	An Abstract is enclosed.					
	Sheets of Proposed Corrected Drawings are enclosed.					
	A Certified Copy of each of the following applications:					
	is enclosed.					
	An Associate Power of Attorney is enclosed.					
	Information Disclosure Statement.					
	Attached Form 1449.					
	A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.					
	Appended Material as follows:					
	Other Material as follows: Amendment to Comply with Sequence Listing  Requirements; Statement to Support Filing and Submission in Accordance with 37  CFR §§ 1.821 through 1.825; paper copy of Sequence Listing (pages 1-8); computer readable form of Sequence Listing.					

### **FEE CALCULATION**

No Additional Fee is Due.

<b>*******</b>			****	SMALL	ENTITY	NOT SMAL	L ENTITY
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	42	53 (20 MINIMUM)	0	\$9 EACH	\$0	\$18 EACH	\$
INDEP. CLAIMS	1	3 (3 MINIMUM)	0	\$42 EACH	\$0	\$84 EACH	\$
FIRST PR	ESENTATION OF	MULTIPLE DEPE	ENDENT	\$140	\$	\$280	\$
ONE MONTH EXTENSION OF TIME				\$55	\$55	\$110	\$
☐ TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$
☐ THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$
☐ FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$
☐ FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$
☐ LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$ )
☐ TERMINAL DISCLAIMER				\$55	\$	\$110	\$
□ OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE \$55.00 \$					\$		

- A check is enclosed in the foregoing amount due.
- Petition is hereby made under 37 C.F.R. 1.136(a) (fees: 37 C.F.R. § 1.17(a)(1)-(4) to extend the time for response to the Office Action of April 23, 2002 to and through August 23, 2002 comprising an extension of the shortened statutory period of one month(s).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified

application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.

The Commissioner is authorized to charge payment of the following fees and to reany overpayment associated with this communication or during the pendency of the application to Deposit Account 23-3050. This sheet is provided in duplicate.				
	The foregoing amount due for filing this paper.			
	Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.			
	Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).			

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: August 14, 2002

S. Maurice Valla

Registration No. 43,966

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

C 2001 WW